Off-Label Use of Ceftolozane/Tazobactam for the Successful Treatment of Healthcare-Associated Meningitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa in a Polytraumatized Patient-A Case Report

被引：0

作者：

Dubler, Simon ^{[1
,2
]}

Brenner, Thorsten ^{[1
,2
]}

Zimmermann, Stefan ^{[3
]}

Mokry, Theresa ^{[4
,5
]}

Roehr, Anka ^{[6
]}

Richter, Daniel C. ^{[1
]}

Heininger, Alexandra ^{[7
]}

Weigand, Markus A. ^{[1
]}

机构：

[1] Heidelberg Univ Hosp, Dept Anaesthesiol, Neuenheimer Feld 110, D-69120 Heidelberg, Germany

[2] Univ Hosp Essen, Dept Anesthesiol & Intens Care Med, Hufelandstr 55, D-45147 Essen, Germany

[3] Heidelberg Univ Hosp, Div Bacteriol, Dept Infect Dis Med Microbiol & Hyg, D-69120 Heidelberg, Germany

[4] Heidelberg Univ Hosp, Diagnost & Intervent Radiol, Neuenheimer Feld 110, D-69120 Heidelberg, Germany

[5] German Canc Res Ctr Heidelberg, Neuenheimer Feld 280, D-69120 Heidelberg, Germany

[6] Heidenheim Hosp, Dept Clin Pharm, Schlosshaustr 100, D-89522 Heidenheim, Germany

[7] Mannheim Univ Hosp, Unit Hosp Hyg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany

来源：

REPORTS | 2022年 / 5卷 / 03期

关键词：

ceftolozan; tazobactam; Pseudomonas aeruginosa; drug resistance; case report; meningitis; BRAIN-BARRIER; DOUBLE-BLIND; INFECTIONS; TAZOBACTAM;

D O I：

10.3390/reports5030033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Hospital-acquired infections with extensively drug-resistant (XDR) Pseudomonas aeruginosa (PA) have become a worrisome concern because of unfavorable outcomes and limited antimicrobial treatment options. Studies with new antimicrobial substances against XDR-PA show very promising results in different infection types, but the data for central nervous system (CNS) infections are scarce. Case presentation: Here, we report the case of a young patient with healthcare-associated meningitis caused by XDR-PA following severe craniocerebral injury. An off-label use of high-dose ceftolozane/tazobactam (C/T) monotherapy was administered for 10 days in parallel with source-controlling measures. Clinical and microbial recovery could be accomplished promptly. Conclusion: In patients with hospital-acquired CNS infections due to XDR-PA, C/T might be a new, safe and effective alternative with fewer adverse effects compared to older polymyxin- or aminoglycoside-based regimens.

引用

页数：11

共 33 条

[31] Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
Tirlangi, Praveen Kumar
Wanve, Bala Saheb
Dubbudu, Ramakanth Reddy
Yadav, Boorgula Sushma
Kumar, L. Siva
Gupta, Anand
Sree, Racha Amarthya
Challa, Hari Priya Reddy
Reddy, P. Naveen
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (08)
[32] Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
Dubey, Dilip
Roy, Manish
Shah, Tajamul H. H.
Bano, Noor
Kulshrestha, Vidushi
Mitra, Sandeep
Sangwan, Pushpender
Dubey, Madhulika
Imran, Ali
Jain, Bhawna
Velmurugan, Aravind
Bakthavatchalam, Yamuna Devi
Veeraraghavan, Balaji
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2023, 22 (01)
[33] Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
Dilip Dubey
Manish Roy
Tajamul H. Shah
Noor Bano
Vidushi Kulshrestha
Sandeep Mitra
Pushpender Sangwan
Madhulika Dubey
Ali Imran
Bhawna Jain
Aravind Velmurugan
Yamuna Devi Bakthavatchalam
Balaji Veeraraghavan
Annals of Clinical Microbiology and Antimicrobials, 22

← 1 2 3 4 →